Synopsis
Synopsis
0
EU WC
0
VMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Chloride, Magnesium
2. Magnesium Chloride
3. Mgcl2
1. Magnesium Dichloride Hexahydrate
2. Bischofite
3. Polycatan
4. Magnesia Muriatica
5. Magnesium Chloride, Hexahydrate
6. Ccris 3494
7. Magnesium;dichloride;hexahydrate
8. Bischofite (mgcl2.6h2o)
9. Chlorure De Magnesium Hydrate
10. Magnesium Chloride Hydrate (mgcl2.6h2o)
11. Ins No.511
12. Chebi:86345
13. Ins-511
14. 02f3473h9o
15. E-511
16. Chlorure De Magnesium Hydrate [french]
17. Mgcl2.6h2o
18. Magnesium Chloride [usp]
19. Magnesium Chloride [ii]
20. Chembl3185229
21. Dtxsid0020789
22. Magnesium Chloride [fcc]
23. Magnesium Chloride [jan]
24. Unii-02f3473h9o
25. Magnesia Muriatica [hpus]
26. Magnesium Chloride [inci]
27. Magnesium Chloride [vandf]
28. Magnesium(ii)-chloride Hexahydrate
29. Magnesium Chloride [usp-rs]
30. Magnesium Dichloride--water (1/6)
31. Akos015855540
32. Magnesium Chloride [orange Book]
33. Ncgc00248737-01
34. Magnesium Chloride [usp Monograph]
35. Magnesium(ii) Chloride Hexahydrate
36. Magnesium Chloride Hexahydrate [mi]
37. Ft-0628076
38. Magnesium Chloride Hexahydrate A.c.s.reagent
39. Normocarb Component Magnesium Chloride
40. Magnesium Chloride Hexahydrate [who-dd]
41. Magnesium Chloride Component Of Normocarb
42. Magnesium Chloride Hexahydrate 46.5% Min Mgcl2
43. Magnesium Chloride Hexahydrate [ep Monograph]
44. Q19364448
45. 13778-96-6
Molecular Weight | 203.30 g/mol |
---|---|
Molecular Formula | Cl2H12MgO6 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 0 |
Exact Mass | 201.9861352 g/mol |
Monoisotopic Mass | 201.9861352 g/mol |
Topological Polar Surface Area | 6 Ų |
Heavy Atom Count | 9 |
Formal Charge | 0 |
Complexity | 0 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 9 |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
45
PharmaCompass offers a list of Magnesium Chloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Magnesium Chloride manufacturer or Magnesium Chloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Magnesium Chloride manufacturer or Magnesium Chloride supplier.
PharmaCompass also assists you with knowing the Magnesium Chloride API Price utilized in the formulation of products. Magnesium Chloride API Price is not always fixed or binding as the Magnesium Chloride Price is obtained through a variety of data sources. The Magnesium Chloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A CARDIOPLEGIC IN PLASTIC CONTAINER-1 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CARDIOPLEGIC IN PLASTIC CONTAINER-1, including repackagers and relabelers. The FDA regulates CARDIOPLEGIC IN PLASTIC CONTAINER-1 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CARDIOPLEGIC IN PLASTIC CONTAINER-1 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CARDIOPLEGIC IN PLASTIC CONTAINER-1 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CARDIOPLEGIC IN PLASTIC CONTAINER-1 supplier is an individual or a company that provides CARDIOPLEGIC IN PLASTIC CONTAINER-1 active pharmaceutical ingredient (API) or CARDIOPLEGIC IN PLASTIC CONTAINER-1 finished formulations upon request. The CARDIOPLEGIC IN PLASTIC CONTAINER-1 suppliers may include CARDIOPLEGIC IN PLASTIC CONTAINER-1 API manufacturers, exporters, distributors and traders.
click here to find a list of CARDIOPLEGIC IN PLASTIC CONTAINER-1 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CARDIOPLEGIC IN PLASTIC CONTAINER-1 DMF (Drug Master File) is a document detailing the whole manufacturing process of CARDIOPLEGIC IN PLASTIC CONTAINER-1 active pharmaceutical ingredient (API) in detail. Different forms of CARDIOPLEGIC IN PLASTIC CONTAINER-1 DMFs exist exist since differing nations have different regulations, such as CARDIOPLEGIC IN PLASTIC CONTAINER-1 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A CARDIOPLEGIC IN PLASTIC CONTAINER-1 DMF submitted to regulatory agencies in the US is known as a USDMF. CARDIOPLEGIC IN PLASTIC CONTAINER-1 USDMF includes data on CARDIOPLEGIC IN PLASTIC CONTAINER-1's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CARDIOPLEGIC IN PLASTIC CONTAINER-1 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of CARDIOPLEGIC IN PLASTIC CONTAINER-1 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The CARDIOPLEGIC IN PLASTIC CONTAINER-1 Drug Master File in Japan (CARDIOPLEGIC IN PLASTIC CONTAINER-1 JDMF) empowers CARDIOPLEGIC IN PLASTIC CONTAINER-1 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the CARDIOPLEGIC IN PLASTIC CONTAINER-1 JDMF during the approval evaluation for pharmaceutical products. At the time of CARDIOPLEGIC IN PLASTIC CONTAINER-1 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of CARDIOPLEGIC IN PLASTIC CONTAINER-1 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a CARDIOPLEGIC IN PLASTIC CONTAINER-1 Drug Master File in Korea (CARDIOPLEGIC IN PLASTIC CONTAINER-1 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of CARDIOPLEGIC IN PLASTIC CONTAINER-1. The MFDS reviews the CARDIOPLEGIC IN PLASTIC CONTAINER-1 KDMF as part of the drug registration process and uses the information provided in the CARDIOPLEGIC IN PLASTIC CONTAINER-1 KDMF to evaluate the safety and efficacy of the drug.
After submitting a CARDIOPLEGIC IN PLASTIC CONTAINER-1 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their CARDIOPLEGIC IN PLASTIC CONTAINER-1 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of CARDIOPLEGIC IN PLASTIC CONTAINER-1 suppliers with KDMF on PharmaCompass.
A CARDIOPLEGIC IN PLASTIC CONTAINER-1 CEP of the European Pharmacopoeia monograph is often referred to as a CARDIOPLEGIC IN PLASTIC CONTAINER-1 Certificate of Suitability (COS). The purpose of a CARDIOPLEGIC IN PLASTIC CONTAINER-1 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of CARDIOPLEGIC IN PLASTIC CONTAINER-1 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of CARDIOPLEGIC IN PLASTIC CONTAINER-1 to their clients by showing that a CARDIOPLEGIC IN PLASTIC CONTAINER-1 CEP has been issued for it. The manufacturer submits a CARDIOPLEGIC IN PLASTIC CONTAINER-1 CEP (COS) as part of the market authorization procedure, and it takes on the role of a CARDIOPLEGIC IN PLASTIC CONTAINER-1 CEP holder for the record. Additionally, the data presented in the CARDIOPLEGIC IN PLASTIC CONTAINER-1 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the CARDIOPLEGIC IN PLASTIC CONTAINER-1 DMF.
A CARDIOPLEGIC IN PLASTIC CONTAINER-1 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. CARDIOPLEGIC IN PLASTIC CONTAINER-1 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of CARDIOPLEGIC IN PLASTIC CONTAINER-1 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CARDIOPLEGIC IN PLASTIC CONTAINER-1 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for CARDIOPLEGIC IN PLASTIC CONTAINER-1 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture CARDIOPLEGIC IN PLASTIC CONTAINER-1 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain CARDIOPLEGIC IN PLASTIC CONTAINER-1 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CARDIOPLEGIC IN PLASTIC CONTAINER-1 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of CARDIOPLEGIC IN PLASTIC CONTAINER-1 suppliers with NDC on PharmaCompass.
CARDIOPLEGIC IN PLASTIC CONTAINER-1 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CARDIOPLEGIC IN PLASTIC CONTAINER-1 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CARDIOPLEGIC IN PLASTIC CONTAINER-1 GMP manufacturer or CARDIOPLEGIC IN PLASTIC CONTAINER-1 GMP API supplier for your needs.
A CARDIOPLEGIC IN PLASTIC CONTAINER-1 CoA (Certificate of Analysis) is a formal document that attests to CARDIOPLEGIC IN PLASTIC CONTAINER-1's compliance with CARDIOPLEGIC IN PLASTIC CONTAINER-1 specifications and serves as a tool for batch-level quality control.
CARDIOPLEGIC IN PLASTIC CONTAINER-1 CoA mostly includes findings from lab analyses of a specific batch. For each CARDIOPLEGIC IN PLASTIC CONTAINER-1 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CARDIOPLEGIC IN PLASTIC CONTAINER-1 may be tested according to a variety of international standards, such as European Pharmacopoeia (CARDIOPLEGIC IN PLASTIC CONTAINER-1 EP), CARDIOPLEGIC IN PLASTIC CONTAINER-1 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CARDIOPLEGIC IN PLASTIC CONTAINER-1 USP).